Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

Blood Cancer Journal

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and...

  • This study shows that production of neutralizing antibodies against COVID are low in patients with myeloma, and impaired especially in patients receiving anti CD38 antibodies or belantamab.